Table 6.
Antiplasmodial effectiveness of synthesized nanoparticles
| Authors [Reference] | Results on effectiveness of NPs | Results on used controls |
|---|---|---|
| Panneerselvam et al. [47] |
Parasite growth inhibition rate ranged from 26% (25 µg/mL) to 83% (100 µg/mL) IC50 = 50 µg/mL |
Not computable |
| Ponarulselvam et al. [48] |
Parasite growth inhibition rate ranged from 20% (25 µg/mL) to 75% (100 µg/mL) IC50 = 63.64 µg/mLa |
Not computable |
| Kharthik et al. [61] | Nearly 40% inhibition was observed at dose 8 mg/kg/bw | Not computable |
| Mishra et al. [49] | IC50 = 8 µg/mL (Ashoka) | IC50 = 0.5 µg/mL (AgNO3) |
| IC50 = 30 µg/mL (Neem) | No activity up to 40 µg/mL (extract) | |
| Panneerselvam et al. [50] |
Parasite growth inhibition rate ranged from 26.2% (20 µg/mL) to 100% (100 µg/mL) IC50 = 51.46 µg/mLa |
Not computable |
| Rajakumar et al. [51] | IC20 = 4.34 µg/mL, IC50 = 8.704 µg/mL, IC90 = 18.49 µg/mL | AE: IC20 = 1.90, IC50 = 10.29 and IC90 = 64.11 µg/mL |
| Pd(AcO)2: IC20 = 4.49, IC50 = 9.84 and IC90 = 23.046 µg/mL | ||
| Murugan et al. [52] | IC50 = 76.33 µg/mL (3D7), IC50 = 79.13 µg/mL (INDO) | CQ: IC50 = 80 µg/mL (3D7), IC50 = 85 µg/mL (INDO) |
| Jaganathan et al. [62] | IC50 = 49.3 µg/mL (3D7), IC50 = 55.5 µg/mL (INDO) | CQ: IC50 = 81.5 µg/mL (3D7), IC50 = 86.5 µg/mL (INDO) |
| Subramaniam et al. [53] | IC50 = 69.47 µg/mL (3D7), IC50 = 76.33 µg/mL (INDO) | CQ: IC50 = 80 µg/mL (3D7), IC50 = 90 µg/mL (INDO) |
| AE: IC50 = 43.21 µg/mL (3D7), IC50 = 51.16 µg/mL (INDO) | ||
| Panneerselvam et al. [54] | IC50 = 78.12 µg/mL (3D7), IC50 = 88.34 µg/mL (INDO) | CQ: IC50 = 85 µg/mL (3D7), IC50 = 90 µg/mL (INDO) |
| AE: IC50 = 62.04 µg/mL (3D7), IC50 = 71.16 µg/mL (INDO) | ||
| Murugan et al. [55] | IC50 = 72.45 µg/mL (3D7), IC50 = 76.08 µg/mL (INDO) | CQ: IC50 = 80 µg/mL (3D7), IC50 = 85 µg/mL (INDO) |
| AE: IC50 = 51.34 µg/mL (3D7), IC50 = 65.17 µg/mL (INDO) | ||
| Murugan et al. [56] |
Parasite growth inhibition rate ranged from 6.4 to 42.8% IC50 = 63.18 µg/mL (3D7), IC50 = 69.24 µg/mL (INDO) |
CQ: Parasite growth reduced from 51.2% up to 53.6% |
| IC50 = 90 µg/mL (3D7), IC50 = 98.5 µg/mL (INDO) | ||
| AE: Parasite growth reduced from 15.2% up to 58.6% | ||
| IC50 = 82.41 µg/mL (3D7), IC50 = 86.12 µg/mL (INDO) | ||
| Dutta et al. [57] |
AgNP: IC50 = 24.22 ± 2.44 µg/mL (Bark, 3D7) IC50 = 29.09 ± 2.54 µg/mL (Bark, Dd2) IC50 = 28.97 ± 3.21 µg/mL (Leaf, 3D7) IC50 = 34.49 ± 1.42 µg/mL (Leaf, Dd2) |
AE: IC50 = 43.49 ± 3.23 µg/mL (Bark, 3D7) IC50 = 47.66 ± 3.97 µg/mL (Bark, Dd2) |
|
IC50 = 51.70 ± 1.29 µg/mL (Leaf, 3D7) IC50 = 53.37 ± 2.86 µg/mL (Leaf, Dd2) | ||
|
AuNP: IC50 = 49.54 ± 2.34 µg/mL (Bark, 3D7) IC50 = 51.63 ± 2.55 µg/mL (Bark, Dd2) IC50 = 45.49 ± 1.40 µg/mL (Leaf, 3D7) IC50 = 49.38 ± 3.04 µg/mL (Leaf, Dd2) |
CQ: IC50 = 0.371 µg/mL (3D7), IC50 = 1.8 µg/mL (Dd2) | |
| Murugan et al. [63] | IC50 = 83.32 µg/mL (3D7), IC50 = 87.47 µg/mL (INDO) | CQ: IC50 = 92 µg/mL (3D7), IC50 = 96 µg/mL (INDO) |
| Sardana et al. [58] | IC50 = 0.313 to 1.692 µM (3D7) | Not applicable |
| Gandhi et al. [59] | IC50 = 53.42 µg/mL (3D7), IC50 = 59.71 µg/mL (INDO) | CQ: IC50 = 0.021 µg/mL (3D7), IC50 = 0.258 µg/mL (INDO) |
| Rotimi et al. [60] | NPs were inactive against malaria parasites (% viability < 20%) | Not specified |
NPs nanoparticles, AgNPs silver nanoparticles, AuNPs gold nanoparticles, IC20 20% inhibitory concentration, IC50 50% inhibitory concentration, IC90 90% inhibitory concentration, CQ chloroquine, AE aqueous extract
aIC50 was calculated using data coming from the study